Product
BAY1817080
9 clinical trials
8 indications
Indication
Endometriosis Related PainIndication
Overactive BladderIndication
painful diabetic neuropathyIndication
Chronic CoughIndication
Healthy Control ParticipantsIndication
CoughIndication
EndometriosisClinical trial
An Open-label Study to Evaluate the Pharmacokinetics and Safety of BAY 1817080 in Participants With Impaired Renal Function in Comparison to Matched Controls With Normal Renal FunctionStatus: Completed, Estimated PCD: 2021-02-15
Clinical trial
Single-center, Open-label, Non-placebo-controlled, Single-dose Study in Healthy Male Participants to Determine the Pharmacokinetics of BAY 1817080 Oral Solution (Part A) and to Investigate the Pharmacokinetics, Metabolic Disposition and Mass Balance of [14C]BAY 1817080 Oral Solution (Part B)Status: Completed, Estimated PCD: 2020-09-30
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Combined Phase 2a/2b Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Diabetic Neuropathic PainStatus: Terminated, Estimated PCD: 2021-09-23
Clinical trial
Phase 1 Dose Escalation Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of BAY 1817080 in Japanese Healthy Adult Male Participants in a Single-center, Randomized, Single-blind, Placebo-controlled DesignStatus: Completed, Estimated PCD: 2020-09-20
Clinical trial
A Single-center, Randomized, Placebo-controlled, Parallel-group, Double-blind Study to Investigate the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of BAY 1817080 in Chinese Healthy Adult Male Participants.Status: Completed, Estimated PCD: 2021-07-19
Clinical trial
An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BAY 1817080 in Participants With Impaired Hepatic Function (Classified as Child-Pugh A, B or C) in Comparison to Matched Controls With Normal Hepatic FunctionStatus: Completed, Estimated PCD: 2021-06-24
Clinical trial
Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Volunteers to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1817080, Followed by (Part 2), Two-way Crossover Administration of Four Different Doses in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of ConceptStatus: Completed, Estimated PCD: 2019-05-28
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Proof-of-concept Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Overactive Bladder (OAB) Over a 12-week Treatment PeriodStatus: Completed, Estimated PCD: 2021-12-22
Clinical trial
A Randomized, Double-blind, Open for Active Comparator, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Three Different Doses of P2X3 Antagonist (BAY1817080) Versus Placebo and Elagolix 150 mg in Women With Symptomatic EndometriosisStatus: Terminated, Estimated PCD: 2022-01-17